Evidence map›Paper›PMID 37944600›Full record

ReviewSurvey of ophthalmology

In praise of povidone-iodine application in ophthalmology.

Mohammad Soleimani, Ali A Haydar, Kasra Cheraqpour, Haniyeh Zeidabadinejad, Amirreza Esfandiari, Niloofarsadaat Eshaghhosseiny, Alireza Shahmohammadi, Soraya Banz, Ali R Djalilian

Open access · greenAbstract readReview
In one paragraph

Review in Survey of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Adjunctive povidone-iodine forAntimicrobial agents and chemotherapy · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Commercially available antiseptics show highFrontiers in veterinary science · 2025
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Mohammad SoleimaniEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: soleimani_md@yahoo.com.
Ali A HaydarEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ali.haydar01@lau.edu.
Kasra CheraqpourEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: cheraqpourk@gmail.com.
Haniyeh ZeidabadinejadEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: hzeyd92@gmail.com.
Amirreza EsfandiariEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: dramirreza1373@gmail.com.
Niloofarsadaat EshaghhosseinyHarvard Medical University, MA, USA. Electronic address: waterliliniloo84@gmail.com.
Alireza ShahmohammadiIran University of Medical Sciences, Tehran, Iran. Electronic address: alirezashmd@yahoo.com.
Soraya BanzDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; University of Edinburgh, UK. Electronic address: soraya.banz@icloud.com.
Ali R DjalilianDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: adjalili@uic.edu.
Tehran University of Medical Sciences · IRUniversity of Illinois Chicago · USFarabi Hospital · IRHarvard University · USIran University of Medical Sciences · IR

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 1985 to 2025
$14.8M
Novel Therapies for Ocular Chemical InjuriesR01EY024349 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DJALILIAN, ALI R · 2015 to 2020
$2.1M
Phase I Study of Mesenchymal Stromal Cell Secretome for Promoting Corneal RegenerationUH3EY031809 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALI R DJALILIAN · 2021 to 2026
$1.6M
NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024349NEI NIH HHS UH3 EY031809
6 · The paper itself

Abstract

Polyvinyl pyrrolidone or povidone-iodine (PVP-I) is a water-soluble complex formed by the combination of iodine and a water-soluble polymer, polyvinyl pyrrolidone. This complex exerts bactericidal, fungicidal, and virucidal action by gradually releasing free iodine at the site of application to react with pathogens. In ophthalmology, PVP-I is used as a disinfectant and antiseptic agent for preoperative preparation of the skin and mucous membranes and for treating contaminated wounds. PVP-I has been shown to reduce effectively the risk of endophthalmitis in various ocular procedures, including cataract surgery and intravitreal injections; however, it has also been used in the treatment of conjunctivitis, keratitis, and endophthalmitis, with promising results especially in low-resource situations. PVP-I has been associated with complications such as postoperative eye pain, persistent corneal epithelial defects, ocular inflammation, and an attendant risk of keratitis. In cases of poor PVP-I tolerance, applying PVP-I at lower concentrations or using alternative antiseptics such as chlorhexidine should be considered. We provide an update on the efficacy of PVP-I in the prophylaxis and treatment of conjunctivitis, keratitis, and endophthalmitis and a comprehensive analysis of the current literature regarding the use of PVP-I in the management of these ocular conditions. Also, PVP-I-related adverse effects and toxicities and its alternatives are discussed. The goal is to present a thorough evaluation of the available evidence and to offer practical recommendations for clinicians regarding the therapeutic usage of PVP-I in ophthalmology.

Indexed as

Anti-Infective Agents, LocalCataract ExtractionConjunctivitisEndophthalmitisIodineKeratitisOphthalmologyHumansPolyvinylsPovidonePovidone-IodineWaterAnti-Infective Agents, LocalIodinePolyvinylsPovidonePovidone-IodineWaterConjunctivitisEndophthalmitisEyeKeratitisOphthalmologyPolyvinyl pyrrolidonePovidone-iodine

Identifiers

PMID37944600
PMCPMC10978307
OpenAlexW4388492368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.